Reporting on patient's body mass index (BMI) in recent clinical trials for patients with breast cancer: a systematic review.
Josephine Van CauwenbergeKaren Van BaelenMarion MaetensTatjana GeukensHa Linh NguyenInes NevelsteenAnn SmeetsAnne DeblanderPatrick NevenStijn KoolenHans WildiersKevin PunieChristine DesmedtPublished in: Breast cancer research : BCR (2024)
Patient adiposity is hardly considered as most novel drug treatments are given in a fixed dose. BMI is generally not reported in recent trials and few secondary analyses are performed. Given the prevalence of patients with obesity and the impact obesity can have on pharmacokinetics and cancer biology, more attention should be given by investigators and study sponsors to reporting patient's BMI and evaluating its impact on treatment efficacy and toxicity.
Keyphrases
- body mass index
- weight gain
- insulin resistance
- case report
- clinical trial
- metabolic syndrome
- type diabetes
- weight loss
- adverse drug
- physical activity
- working memory
- risk factors
- papillary thyroid
- randomized controlled trial
- young adults
- squamous cell
- lymph node metastasis
- double blind
- placebo controlled
- oxide nanoparticles